SBIR-STTR Award

In Situ Remediation of Methyl Tert-Butyl Ether (MTBE) Using Bioaugmentation
Award last edited on: 4/3/2022

Sponsored Program
SBIR
Awarding Agency
NSF
Total Award Amount
$595,567
Award Phase
2
Solicitation Topic Code
-----

Principal Investigator
Paul B Hatzinger

Company Information

Envirogen Inc

4100 Quakerbridge Road
Lawrenceville, NJ 08648
   (609) 936-9300
   N/A
   www.envirogen.com
Location: Multiple
Congr. District: 12
County: Mercer

Phase I

Contract Number: ----------
Start Date: ----    Completed: ----
Phase I year
1999
Phase I Amount
$99,985
The gasoline additive methyl tert-butyl ether (MTBE) is the second most prevalent contaminant in groundwater in the United States, and there are currently no economical technologies for its removal from the water supply. Envirogen scientists have recently isolated a novel bacterium (ENV 735) that utilizes MTBE as a growth substrate. This is only the second report of a pure culture that is capable of growing on MTBE. The objective of this Phase I Proposal is to evaluate the potential application of strain ENV 735 for in situ bioremediation of MTBE. Aquifer microcosms will be used to measure the kinetics of MTBE degradation by ENV 735 under different microbiological and geochemical conditions. In addition, the pathway of MTBE degradation by ENV 735 will be studied, and experiments will be conducted to determine whether the metabolic capacity to degrade MTBE is shared among other bacteria of the same class as ENV 735. The data from this study will be used to assess the feasibility of using ENV 735 and similar microorganisms for in situ remediation of MTBE in contaminated aquifers. The commercial potential for a remediation technology that allows rapid, efficient, and cost effective destruction of MTBE in groundwater is tremendous. This potential derives from the following factors: (1) MTBE is the second most prevalent groundwater contaminant in the United States (e.g., 79 % of wells in urban Denver were recently found to be contaminated); (2) traditional technologies are ineffective at removing this contaminant from groundwater, and (3) MTBE has been shown to cause cancer in laboratory animals, thus regulatory concern is high. Based on these factors, ENVIROGEN analysts expect MTBE to be one of the most active remediation markets over the next decade.

Phase II

Contract Number: ----------
Start Date: ----    Completed: ----
Phase II year
2001
Phase II Amount
$495,582
This Small Business Innovation Research (SBIR) Phase II Project is designed to develop and demonstrate a new in situ treatment technology for the destruction of methyl tert-butyl ether (MTBE) in groundwater. The gasoline additive MTBE is the second most prevalent groundwater contaminant in the United States, and there are currently no economical technologies for its removal from the water supply. This technology utilizes a novel bacterium of the species Hydrogenophaga flava (ENV735) for the remediation of MTBE. This bacterium, which was recently isolated by Envirogen scientists, is one of only two bacterial strains discovered that are capable of growth on MTBE. Phase II experiments will be conducted to: (1) assess the movement and distribution of the bacterium in the subsurface; (2) develop an adhesion-deficient strain for improved aquifer distribution; and (3) optimize commercial-scale growth, shipment, and injection of the bacterium for field application. A field demonstration will be conducted to fully test the technology under in situ conditions. The bioaugmentation with ENV735 has broad potential as an in situ remediation technology for MTBE-contaminated aquifers. If the results of the field trial are positive, commercialization of the bioaugmentation technology is anticipated in the short term.